Fintel reports that on January 7, 2025, TD Cowen initiated coverage of CG Oncology (NasdaqGS:CGON) with a Buy recommendation.

CG Oncology, Inc. (CGON – Research Report) received a Buy rating and price target from TD Cowen analyst Tyler Van Buren today. The company’s ...

Investment analysts at TD Cowen began coverage on shares of CG Oncology (NASDAQ:CGON – Get Free Report) in a research report issued to clients and investors on Tuesday, MarketBeat.com reports. The ...

TD Cowen analyst Tyler Van Buren initiated coverage of CG Oncology (CGON) with a Buy rating and no price target The firm says cretostimogene ...

Shares of CG Oncology, Inc. (NASDAQ:CGON – Get Free Report) rose 2.5% during trading on Friday . The stock traded as high as $29.90 and last traded at $29.85. Approximately 328,509 shares changed ...

CG Oncology Inc. IRVINE, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (Nasdaq: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a ...

CG Oncology shares are trading lower by 9.2% during Wednesday's session. The company announced it filed an underwritten public offering of 7.3 million shares of its common stock. Discover Fast ...

CG Oncology, Inc. (NASDAQ:CGON) reported positive results just about a week ago from its phase 3 BOND-003 study using its oncolytic immunotherapy candidate Cretostimogene for the treatment of BCG ...

IRVINE, Calif., Dec. 11, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (Nasdaq: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone ...

CG Oncology closed a public offering of 9.2 million shares, raising $238 million for bladder cancer therapy development. CG Oncology, Inc., a clinical biopharmaceutical company specializing in ...